Business Description
Shedir Pharma Group SpA
ISIN : IT0005379620
Compare
Compare
Traded in other countries / regions
SHE.Italy IPO Date
2019-07-23Description
Shedir Pharma Group SpA is engaged in manufacturing of nutraceuticals, cosmetics and medical devices. Its products are divided into four lines Shedir , Deimos, Phobos, and Menkar. The company's products include capsules, softgels, swallowable and chewable tablets, orosoluble powders, granules, oral solutions, drops for oral use, sprays for oral, sublingual and nasal use, Creams and gels for cosmetic use, and Spray for topical use.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.33 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | 0.46 | |||||
| Interest Coverage | 35.63 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.95 | |||||
| Beneish M-Score | -1.99 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.2 | |||||
| 3-Year EBITDA Growth Rate | 16.8 | |||||
| 3-Year EPS without NRI Growth Rate | 13.5 | |||||
| 3-Year Book Growth Rate | 10.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 7.48 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.09 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.58 | |||||
| 9-Day RSI | 74.58 | |||||
| 14-Day RSI | 76.8 | |||||
| 3-1 Month Momentum % | 24.1 | |||||
| 6-1 Month Momentum % | 23.47 | |||||
| 12-1 Month Momentum % | 11.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.86 | |||||
| Quick Ratio | 1.86 | |||||
| Cash Ratio | 0.9 | |||||
| Days Inventory | 129.86 | |||||
| Days Sales Outstanding | 64.96 | |||||
| Days Payable | 85.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.32 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 4.53 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 28.81 | |||||
| Operating Margin % | 14.42 | |||||
| Net Margin % | 9.83 | |||||
| FCF Margin % | 8.11 | |||||
| ROE % | 17.32 | |||||
| ROA % | 10.8 | |||||
| ROIC % | 18.62 | |||||
| 3-Year ROIIC % | 13.33 | |||||
| ROC (Joel Greenblatt) % | 37.18 | |||||
| ROCE % | 21.8 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.08 | |||||
| Forward PE Ratio | 8.1 | |||||
| PE Ratio without NRI | 8.95 | |||||
| PEG Ratio | 1.42 | |||||
| PS Ratio | 0.9 | |||||
| PB Ratio | 1.47 | |||||
| Price-to-Tangible-Book | 1.7 | |||||
| Price-to-Free-Cash-Flow | 11.17 | |||||
| Price-to-Operating-Cash-Flow | 5.93 | |||||
| EV-to-EBIT | 5.36 | |||||
| EV-to-EBITDA | 3.74 | |||||
| EV-to-Revenue | 0.77 | |||||
| EV-to-FCF | 9.46 | |||||
| Price-to-GF-Value | 0.89 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.5 | |||||
| Price-to-Graham-Number | 0.82 | |||||
| Price-to-Net-Current-Asset-Value | 2.35 | |||||
| Earnings Yield (Greenblatt) % | 18.66 | |||||
| FCF Yield % | 9.07 | |||||
| Forward Rate of Return (Yacktman) % | 8.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shedir Pharma Group SpA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 61.793 | ||
| EPS (TTM) (€) | 0.535 | ||
| Beta | 0.57 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.4 | ||
| Volatility % | 30.48 | ||
| 14-Day RSI | 76.8 | ||
| 14-Day ATR (€) | 0.023455 | ||
| 20-Day SMA (€) | 4.855 | ||
| 12-1 Month Momentum % | 11.52 | ||
| 52-Week Range (€) | 3.34 - 4.88 | ||
| Shares Outstanding (Mil) | 11.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shedir Pharma Group SpA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shedir Pharma Group SpA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shedir Pharma Group SpA Frequently Asked Questions
What is Shedir Pharma Group SpA(MIL:SHE)'s stock price today?
The current price of MIL:SHE is €4.86. The 52 week high of MIL:SHE is €4.88 and 52 week low is €3.34.
When is next earnings date of Shedir Pharma Group SpA(MIL:SHE)?
The next earnings date of Shedir Pharma Group SpA(MIL:SHE) is .
Does Shedir Pharma Group SpA(MIL:SHE) pay dividends? If so, how much?
Shedir Pharma Group SpA(MIL:SHE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers